Emerging biological treatments for uterine cervical carcinoma. - Wikidata - wikimedia - TriplyDB

Emerging biological treatments for uterine cervical carcinoma.

Emerging biological treatments for uterine cervical carcinoma.

http://www.wikidata.org/entity/Q37540968

about

HPV-Testing in Follow-up of Patients Treated for CIN2+ Lesions Immunotherapy of HPV-associated cancer: DNA/plant-derived vaccines and new orthotopic mouse models Wnt5A expression is associated with the tumor metastasis and clinical survival in cervical cancer.Trial Watch: Peptide-based anticancer vaccines.Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervical cancer.Angiogenesis and antiangiogenic agents in cervical cancer.Up-regulation of ROR2 is associated with unfavorable prognosis and tumor progression in cervical cancer Marketed nonsteroidal anti-inflammatory agents, antihypertensives, and human immunodeficiency virus protease inhibitors: as-yet-unused weapons of the oncologists' arsenal.DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis.Expression of VEGF and HIF-1α in locally advanced cervical cancer: potential biomarkers for predicting preoperative radiochemotherapy sensitivity and prognosis Immunologic treatments for precancerous lesions and uterine cervical cancer.Mutation analysis of EGFR and its correlation with the HPV in Indian cervical cancer patients.HPV-type-specific response of cervical cancer cells to cisplatin after silencing replication licensing factor MCM4.Clinical Significance and Prognosis Value of Wnt Signaling Pathway in Cervical Cancer.A plant protein signal sequence improved humoral immune response to HPV prophylactic and therapeutic DNA vaccines.Using HIV drugs to target human papilloma virus.Wnt signaling in cervical cancer?Neoadjuvant Therapy of Cervical Carcinoma with the Angiogenesis Inhibitor Bevacizumab: a Single-Centre Analysis

P2860

Q26771420-65706F2A-9775-462C-94F3-AC747F3D8FF9 Q28083154-9B03A564-3CA3-4211-A9D1-183ADA50FB64 Q34371581-4A3ADAAD-34FD-42A8-A212-9225A6CD1AD4 Q34483345-1197341D-35CB-4874-A0F3-F393F03013FF Q34561618-63EA596D-049A-4697-BD8A-8279F3A9B141 Q34655335-33EC6D75-4BA1-4E05-A777-79CCBBEED3DD Q35145060-C5666851-B17D-4130-93BD-0D57AF82B81A Q35653603-7A0850F4-55F7-49C0-93D3-1D04387879BC Q35941085-5DD81F6A-D60F-45F2-9851-6E6F5AA9BB20 Q36944132-BBA0FD4F-2CEB-4FF2-AA47-362DCA8E6941 Q37703113-86C3877F-ED21-40BA-A900-5F9C2743EB28 Q38804094-60045AE7-6E62-4264-A256-540EA4FBC4FA Q38851565-0FCAED67-9B67-4BCD-A7DB-CB3ADEF61A9A Q39181645-AA81FDC0-11E1-46BD-A9E9-EE20018326CA Q40360089-03407860-7947-490B-BE18-1B2F220AF723 Q45345828-B07A2660-C40B-4829-BE08-79B6E79B3A06 Q55017017-D586A748-3575-4764-97BE-79706BB8A868 Q58735557-40688DA1-A90A-453B-9259-D67D608860DE

P2860

Emerging biological treatments for uterine cervical carcinoma.

http://www.wikidata.org/entity/Q37540968

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 05 January 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Emerging biological treatments for uterine cervical carcinoma.

@en

Emerging biological treatments for uterine cervical carcinoma.

@nl

type

label

Emerging biological treatments for uterine cervical carcinoma.

@en

Emerging biological treatments for uterine cervical carcinoma.

@nl

prefLabel

Emerging biological treatments for uterine cervical carcinoma.

@en

Emerging biological treatments for uterine cervical carcinoma.

@nl

P1433

Q37540968-F9B60D52-151E-4678-A256-CD9586DD426A

P1476

Q37540968-96AC076C-67AA-4C7B-B3A1-F787CAE19B80

P2093

Q37540968-2E5C95D6-B9EA-4685-90B6-1D285C5E4690

Q37540968-48D9DD8B-AF0E-44C8-B9E7-A0010BDDDB7A

Q37540968-5BFB494B-1C7A-4DF1-B623-49BD28352F2F

Q37540968-771C4FC5-11A6-47BF-8993-6989D7F4E8D6

Q37540968-7BF9F7CE-C250-422A-A234-BC3E19A37565

Q37540968-A88F5E2D-AA1D-482F-A72F-7441E2C49BA9

Q37540968-BF4DDF32-E942-46AB-AF50-989FAF8A3934

Q37540968-BF8A7CB4-3A7C-442C-A986-7EA64F069137

Q37540968-D3A31F76-15EB-4AA0-9F40-435884F89B21

Q37540968-E7B5ECDA-49BD-49F8-B241-C368076555F6

P2860

Q37540968-0259C9B3-8B41-4D55-BC0B-D8EDE364B6F0

Q37540968-04CA5560-B5C1-420E-8A91-F9AC9306EAE4

Q37540968-0AA69EB5-2C07-4DF1-8636-444753688281

Q37540968-0ADCCAA8-8F93-4BC2-8428-070E1063FC4B

Q37540968-0B52EFAA-BE90-4E91-916D-9361A12A401F

Q37540968-0BC62F34-026E-4C97-80F7-215355C5B730

Q37540968-0CABEBCB-09C2-460B-A6FB-AAD2946DFA9A

Q37540968-1040C9D5-8014-4D2A-9DCD-9D6A40648CEF

Q37540968-12C03FBC-2D07-40B9-8494-BF8AAC728C6C

Q37540968-13856F75-4ACB-4D37-81AA-2D18D350E4CB

P304

Q37540968-BFCFA4A0-3BA4-4E62-91F5-F60B86B39024

P31

Q37540968-8DC99F66-176C-4483-ACB9-46C2047667AF

P356

Q37540968-31A698BA-8185-4E6C-9787-4B75EC99554F

P433

Q37540968-E697DCEC-39AC-48BC-B74E-B2E39D2136C6

P478

Q37540968-5E7C29FC-6858-4A58-BF26-8CB109048E2F

P50

Q37540968-5BD433DE-692C-47A8-B958-B1F4D2CDA63F

Q37540968-C918F4A9-6F33-4C1D-9A84-17A234AC829B

Q37540968-D47CDD06-3E00-4757-B1A4-94710513B4BD

Q37540968-E685D4A2-158D-49F7-A92B-D968FF587A22

P577

Q37540968-4253B150-5835-45B7-934A-752BEAC77667

P5875

Q37540968-344DC268-1AE4-4B9F-A735-2FE3B680677F

P698

Q37540968-01927AD7-939E-408E-8077-239D47B01F35

P932

Q37540968-13AE7B77-93FE-4CAA-AD78-9AB6E83DB49E

P356

P1433

Journal of Cancer

P1476

Emerging biological treatments for uterine cervical carcinoma

@en

P2093

Aldo Venuti

http://www.w3.org/2001/XMLSchema#string

Cristina Vincenzoni

http://www.w3.org/2001/XMLSchema#string

Emanuela Mancini

http://www.w3.org/2001/XMLSchema#string

Federica Tomao

http://www.w3.org/2001/XMLSchema#string

Giuseppe Giovinazzo

http://www.w3.org/2001/XMLSchema#string

Laura Pizzuti

http://www.w3.org/2001/XMLSchema#string

Luciano Mariani

http://www.w3.org/2001/XMLSchema#string

Luigi Di Lauro

http://www.w3.org/2001/XMLSchema#string

Marcello Maugeri-Saccà

http://www.w3.org/2001/XMLSchema#string

Silverio Tomao

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

Therapy of human papillomavirus-related disease

Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin

Association of epigenetic inactivation of the WRN gene with anticancer drug sensitivity in cervical cancer cells

Stressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells

The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product

ERBB receptors and cancer: the complexity of targeted inhibitors

Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study

P304

86-97

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7150/JCA.7963

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Maddalena Barba

P577

2014-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260092055

http://www.w3.org/2001/XMLSchema#string

P698

24494026

http://www.w3.org/2001/XMLSchema#string

P932

3909763

http://www.w3.org/2001/XMLSchema#string